Target intelligence / Profile preview

SR-related CTD associated factor 8 (SCAF8)

Target
SCAF8
Molecular classification
Other (RNA-binding protein, Transcription regulation factor)
01

Overview

SR-related CTD associated factor 8 (SCAF8) is an RNA-binding protein involved in controlling mRNA processing during transcription in human cells. SCAF8 acts as an anti-terminator protein by suppressing the use of early, alternative polyadenylation sites, thereby preventing premature transcript termination and the production of non-functional, truncated mRNAs and proteins. It associates with the phosphorylated C-terminal domain (CTD) of RNA polymerase II, binds nascent RNA upstream of early polyA sites, and independently functions as a positive elongation factor for transcript progression. SCAF8 is broadly expressed across tissues, localizes to the nucleoplasm, and is essential for proper gene expression. It acts redundantly with SCAF4 for its anti-termination function; lack of both factors is lethal to cells due to widespread disruption of mRNA maturation. Currently, no approved drugs or small molecules target SCAF8 directly, and it is not regarded as a therapeutic target in standard pharmacology databases.

Other names
SR-related and CTD-associated factor 8CCAP7KIAA1116CDC5L complex-associated protein 7RNA-binding motif protein 16RBM16SR-like CTD-associated factor 8protein SCAF8
02

Biological functions

Negative regulation of termination of RNA polymerase II transcription (poly(A)-coupled)Positive regulation of DNA-templated transcription elongationmRNA anti-termination (prevents early termination by suppressing use of early, alternative polyadenylation sites)RNA binding
03

Disease associations

Other (No direct disease association identified as a primary therapeutic target; associations reported with syndromic conditions such as Coffin-Siris syndrome 1, though not established as a causative target for therapeutic intervention)
04

Safety considerations

Loss of both SCAF4 and SCAF8 is cell-lethal due to essential roles in mRNA processing; disruption leads to aberrant, truncated proteins, which may be toxic

Beyond the preview

Go deeper on SR-related CTD associated factor 8 (SCAF8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR-related CTD associated factor 8 (SCAF8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call